By PPH Foundation

For decades, the global medical community relied on visual estimation to assess blood loss after childbirth. However, this traditional method has long been recognized as highly inaccurate, typically leading to a severe underestimation of volume (Williams et al., 2024).

In the high-stakes environment of a delivery room, guessing how much a bedsheet or surgical pad is soaked can mean the difference between life and death. Today, a profound shift in maternal health is underway, driven by the introduction of simple, calibrated blood-collection drapes and an overhauled understanding of clinical action thresholds.

The traditional standard established by the World Health Organization historically defined postpartum haemorrhage as a blood loss of 500 mL or more within the first 24 hours of a vaginal delivery (Yunas, n.d.).

While this benchmark provided a statistical definition, relying on visual inspection meant that healthcare providers frequently missed the window for early intervention. Because typical signs of hypovolemia do not usually manifest until a woman has already lost approximately 25% of her total blood volume, waiting for a visual confirmation of 500 mL of blood often results in delayed care (Begum, n.d.).

To bridge this gap, modern protocol now integrates an under-buttock, plastic calibrated blood-collection drape placed beneath the mother immediately after delivery (Akter, n.d.). This sterile, fold-out sheet features explicit measurement lines that act as objective warning and action points (Williams et al., 2024).

By allowing clinicians to instantly read the collected volume rather than make a "guesstimate," clinical care processes have become significantly more objective.

Crucially, global health agencies and massive research initiatives have re-engineered the criteria for triggering medical interventions. Under newer frameworks, such as the landmark E-MOTIVE trial, a dual-layered threshold has been implemented. The first trigger occurs at a measured blood loss of 500 mL regardless of clinical appearance; however, the more revolutionary breakthrough is the secondary trigger set at just 300 mL (Gudu, n.d.).

If a woman shows a quantified blood loss of 300 mL combined with just one abnormal clinical observation; such as altered uterine tone, altered consciousness, or a destabilizing vital sign like tachycardia or hypotension, healthcare providers are mandated to immediately initiate a first-response treatment bundle (Begum, n.d.).

This proactive approach recognizes that women with pre-existing conditions like severe prenatal anaemia are highly vulnerable and can experience a catastrophic hemodynamic impact from much smaller volumes of blood loss (Begum, n.d.).

By combining the structural precision of calibrated drapes with the lower, 300 mL clinical trigger, the medical field is moving away from reactive crisis management and toward rapid, protocolized prevention.

This unified front, heavily supported by international bodies like FIGO and the World Health Organization, has fundamentally altered the trajectory of maternal emergency care (Begum, n.d.).

Reflecting on the real-world implementation of these life-saving protocols on the continent, Prof Moses Obimbo, the Project Lead at the End Postpartum Haemorrhage Initiative, underscores the immense systemic value of this shift. According to Prof Obimbo, the power of the 300mL trigger and calibrated drapes lies in removing the dangerous guesswork from the labor ward.

He notes that by giving healthcare providers an objective, standardized metric to act early, we are effectively shifting the narrative from fighting a crisis to preventing one entirely, ensuring that no mother loses her life because a warning sign was missed.

Sources

• Akter, S. (n.d.). Detection and management of postpartum haemorrhage: Qualitative evidence on healthcare providers' knowledge. Detection and Management of Postpartum Haemorrhage - Pure.
• Begum, F. (n.d.). FIGO recommendations on objective measurement of blood loss after birth for early detection of postpartum hemorrhage. Amsterdam UMC.
• Gudu, W. (n.d.). Introducing the E-MOTIVE bundle for the management of postpartum hemorrhage: Perceptions of health professionals and perceived barriers to its implementation in Sub-Saharan Africa. PMC.
• Williams, E. V., Goranitis, I., Oppong, R., Perry, S. J., Devall, A. J., Martin, J. T., Mammoliti, K. M., Beeson, L. E., Sindhu, K. N., Galadanci, H., Alwy Al-beity, F., Qureshi, Z., Hofmeyr, G. J., Moran, N., Fawcus, S., Mandondo, S., Middleton, L., Hemming, K., Oladapo, O. T., Gallos, I. D., Coomarasamy, A., & Roberts, T. E. (2024). A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial. Nature Medicine, 30, 2343-2348. https://doi.org/10.1038/s41591-024-03069-5
• Yunas, I. (n.d.). Tests for diagnosis of postpartum haemorrhage at vaginal birth. PMC - NIH.
• Image by Freepik